Navigation Links
EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
Date:6/3/2009

HUNTSVILLE, Ala., June 3 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Khursheed Anwer, Ph.D., has been promoted to President and Chief Scientific Officer. He will succeed Danny H. Lewis, Ph.D., who has retired from the position of President and Chief Executive Officer. Dr. Lewis will continue to support the company on scientific and business affairs and retain his position on EGEN's Board of Directors.

"The Board would like to thank Dr. Lewis for his invaluable contributions over the past five years. Under Dr. Lewis' leadership EGEN has developed a proprietary technology platform, moved a novel cancer product through two human clinical trials, developed a family of RNAi delivery technologies and put the Company on solid financial footing. We are delighted that he will continue his contributions as a member of EGEN's Board of Directors," said Milton Harris, Ph.D., Chairman of EGEN. "At the same time, we are excited to have Dr. Anwer assume the role of President. He has demonstrated impressive strategic and leadership skills, advancing EGEN's science from the bench to the clinic. We are pleased to have him lead the continued development of EGEN's novel technology for RNAi delivery and clinical development of its oncology product."

"This is an excellent time to transition EGEN's leadership," said Dr. Lewis. "EGEN is in good shape on all fronts, but especially with the team of people EGEN has in all roles. It has been a pleasure to be part of this group. We are fortunate to have a scientific leader like Dr. Anwer available to take the helm."

Dr. Anwer possesses more than 15 years of management and scientific leadership experience in the biotechnology industry and has authored more than 40 publications during his active career in research and development. He has served EGEN in a variety of scientific leadership positions since 2002, most recently as Senior Vice-President and Chief Scientific Officer. In these positions he has led the execution of EGEN's proprietary discovery and development initiatives leading to EGEN's strong intellectual property position, was instrumental in building EGEN's research and development team and fostered important industry collaborations that are underway.

"I am pleased to have the opportunity to continue my personal contributions to EGEN's success," said Dr. Anwer. "I look forward to working with the Board of Directors and moving EGEN's technology forward to create additional value for our shareholders. We are poised to take the company's novel technology to the next level and make the promise of nucleic acid (DNA, RNAi) therapeutics become a reality."

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit http://www.egeninc.com/ .


'/>"/>
SOURCE EGEN, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
2. Amylin Announces Preliminary Tabulation of Annual Meeting Results
3. Cynosure Announces Presentations at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
5. Assay Designs(TM), Inc. Announces Release of First Available Product for Multiplex Analysis of Heat Shock Proteins
6. Valeritas Announces Appointment of New CEO
7. Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. TorreyPines Therapeutics Announces its Board of Directors Approval of Plan of Liquidation and Dissolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... American ... two additional patents, U.S. Patent Nos. 9,322,133 and 9,322,134, to API and its ... nanocellulose as well as hydrophobic nanocellulose compositions. In addition to these patents ...
(Date:5/5/2016)... BELL, Pa. , May 5, 2016  Why ... Powers and Lorna Weir launching a ... un-agency way? Because they believe that truly helping clients ... world of healthcare now demands a different type of ... strategy lab serving the pharmaceutical, biotechnology and medical device ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... previously announced identification of its first three targets, it has identified a fourth ... beta (Aß), implicated in the development and progression of Alzheimer’s disease (AD). ...
(Date:5/4/2016)... ... 2016 , ... CereScan, the nation’s leader in providing statistically ... Stroke Awareness Month in May. An infographic created by CereScan will be ... will donate $1 up to a maximum of $3,000 through users who share ...
Breaking Biology Technology:
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/9/2016)... , March 9, 2016 This BCC ... future states of the RNA Sequencing (RNA Seq) market ... such as instruments, tools and reagents, data analysis, and ... various segments of the RNA-Sequencing market such as RNA-Sequencing ... Identify the main factors affecting each segment and forecast ...
(Date:3/3/2016)... 2016  FlexTech, a SEMI Strategic Association Partner, awarded ... & Development, Leadership in Education, and, in a category ... th year of the FLEXI Awards and the ... from past years . Judging was done on ... of criteria, by a panel of non-affiliated, independent, industry ...
Breaking Biology News(10 mins):